Recent technology has made it possible to measure DNA methylation profiles in a cost-effective and comprehensive genome-wide manner using array-based technology for epigenome-wide association studies. However, identifying differentially methylated regions (DMRs) remains a challenging task because of the complexities in DNA methylation data. Supervised methods typically focus on the regions that contain consecutive highly significantly differentially methylated CpGs in the genome, but may lack power for detecting small but consistent changes when few CpGs pass stringent significance threshold after multiple comparison. Unsupervised methods group CpGs based on genomic annotations first and then test them against phenotype, but may lack specificity because the regional boundaries of methylation are often not well defined. We present coMethDMR, a flexible, powerful, and accurate tool for identifying DMRs. Instead of testing all CpGs within a genomic region, coMethDMR carries out an additional step that selects co-methylated sub-regions first. Next, coMethDMR tests association between methylation levels within the sub-region and phenotype via a random coefficient mixed effects model that models both variations between CpG sites within the region and differential methylation simultaneously. coMethDMR offers well-controlled Type I error rate, improved specificity, focused testing of targeted genomic regions, and is available as an open-source R package.
INTRODUCTION
Many diseases are caused by a complex interplay of genes and environment factors, such as smoking, poor diet, and lack of exercise. Epigenetic studies investigate the mechanisms that modify the expression levels of selected genes without changes to the underlying DNA sequence. The study of these epigenetic patterns hold excellent promise for detecting new regulatory mechanisms that may be susceptible to modification by environmental factors, which in turn increase the risk of disease. Among epigenetic modifications, DNA methylation is the most widely studied. The addition or removal of a methyl group at the 5th position of a cytosine is the key feature of DNA methylation. Alterations of DNA methylation levels have been shown to be involved in many diseases (1) , such as cancers (2) (3) (4) and neurodegenerative diseases (5) (6) (7) .
While whole-genome bisulfite sequencing is still too costly for large epidemiologic studies, recent technology has made it possible to measure DNA methylation profiles in a cost-effective and comprehensive genome-wide manner using array-based technology such as the Infinium MethylationEPIC BeadChip Kit (8) , which allows researchers to interrogate more than 850,000 methylation sites per sample at single-nucleotide resolution. The first wave of epigenome analysis tools have focused on comprehensive DNA methylation analysis of single base sites, that is, identifying differentially methylated CpG sites, while more recent effort have shifted to analyzing differentially methylated regions (DMRs) (9) (10) (11) .
The shift to DMR analyses are driven by both biological and statistical reasons. Biologically, it has been observed that methylation levels are strongly correlated across the genome and methylation often occurs as a regional phenomenon (12) . In the study of complex diseases, various studies have reported functionally-relevant genomic regions, such as CpG islands (13) or CpG island shores (14) , are associated with diseases. While changes at single sites should not be overlooked, DMRs have increasingly been deemed the hallmarks of differential methylation and replication of DMRs are often more successful compared with changes at single sites (15, 16) . Statistically, because of the large number of CpG sites interrogated by methylation arrays, testing regions rather than individual CpGs can help improve power by reducing the number of tests conducted. In addition, while effect size in a single CpG might be small, by borrowing information from all the CpGs within a region, statistical test for regions can more effectively leverage information within the region to increase sensitivity and specificity.
A number of statistical methods for identifying DMRs have been proposed (10, 11, (17) (18) (19) (20) , reviewed (21, 22) , and compared (23) (24) (25) . Methods for DMR identification can be classified into supervised and unsupervised methods. Supervised methods (e.g. bumphunter (17) , DMRcate (10), and probeLasso (11)) typically start with computing p-values for differential methylation at individual CpG sites, and then scan the genome to identify regions with adjacent low p-values. The statistical significance of these regions is then computed by combining individual CpG p-values in the region using methods such as Stouffer's Z (10) . However, a challenge with supervised methods is that they may lack power for detecting small but consistent changes when few CpGs pass stringent significance threshold after multiple comparison (25) .
An alternative strategy is to use an unsupervised approach, which defines relevant regions across the genome first, independently of any phenotype information, and then tests methylation levels in these predefined regions against a phenotype (19, 20, 26) . In this study, we propose a new unsupervised approach for testing differential methylation in regions against continuous phenotype such as age. Table 1 lists several previously proposed unsupervised methods. A challenge with unsupervised approaches is their lack of specificity. Unlike gene expression data, the regional boundary of DNA methylation is often not well defined. Therefore, currently available approaches that summarize methylation levels in a region using mean or median methylation levels of the CpGs within the region may have results that vary depending on the boundaries of the region. In addition, when testing associations between phenotype and the summarized methylation levels in a genomic region, the spatial correlations between CpG sites within the region is ignored.
Here we present coMethDMR, a new unsupervised approach that optimally leverages covariations among CpGs within genomic regions to identify genomic regions associated with continuous phenotypes. Instead of testing all CpGs within a genomic region, coMethDMR carries out an additional step that clusters co-methylated sub-regions without using any outcome information. Next, coMethDMR tests association between methylation within the sub-region and continuous phenotype using a random coefficient mixed effects model (27) , which models both variations between CpG sites within the region and differential methylation simultaneously.
In the following sections, we provide methodological details of the coMethDMR analysis pipeline and compare this new method with several existing tools. The advantages of coMethDMR is demonstrated using both simulated and real methylation datasets. We show that the additional CpG selection step (subregion identification) improves power substantially while preserving Type I error rate. In addition, the new random coefficient model improves specificity and is robust against association signals from outlier CpGs when detecting changes in differential methylation in the regions. Figure 1 shows the workflow of the coMethDMR analysis pipeline. There are two major steps in the coMethDMR pipeline: (1) within a genomic region, identify the sub-region with contiguous and comethylated CpGs, and (2) test association of CpG methylation in the sub-region with phenotype, while modelling for variabilities among the CpGs simultaneously.
MATERIAL AND METHODS

The coMethDMR analysis pipeline
In the first step, the genome will be divided into regions by taking advantage of methylation array annotations. Because the Illumina chips target methylation sites primarily at genic regions and CpG islands (CGIs, regions in the genome where there are more CG dinucleotides found than expected by chance), the regions can be defined based on their relations to genes or CGIs. Figure 2A shows correlation between methylation levels among CpGs in an example of a genomic region corresponding to the CGI located at chr10:100028236-100028499. This region includes 7 CpG probes ordered by their locations on the chromosome. Note that in spite of belonging to the same CGI, only the last 4 probes constitute the co-methylated region. To select the co-methylated region, we use the rdrop statistic, which is the correlation between each CpG with the sum of methylation levels in all other CpGs ( Fig 2B) . Note that in this example, the co-methylated region consists of all the contiguous CpGs with rdrop statistics greater than 0.5. We evaluated the sensitivity and specificity of the rdrop statistic at identifying co-methylated CpGs in the subsection "Optimal parameter for in coMethDMR pipeline" below.
In the second step, to simultaneously model variations among the co-methylated CpGs as well as association with phenotype, we propose a random coefficient mixed model for testing groups of CpGs against phenotype. Figure 3 Table 1 .
RESULTS
Optimal parameter for in coMethDMR pipeline
The only parameter in the entire coMethDMR pipeline is the rdrop threshold in the identification of comethylated sub-regions within a genomic region ( Figure 2B ). These rdrop statistics are the leave-oneout correlations between each CpG with the sum of methylation levels in all other CpGs. The comethylated regions can be identified by ordering the CpGs by location, and selecting contiguous CpGs with leave-one-out correlations greater than a pre-specified threshold (rdrop), such as 0.5.
Simulation study 1:
We conducted an analysis to assess the sensitivity and specificity of different rDrop values at identifying co-methylated CpGs. For each of the 19977 CGI regions with at least 3
CpGs, we computed pairwise correlations of the CpGs within each CGI region. Next, we selected regions with 3, 5, or 8 CpGs (parameter ncpgs) that have average pairwise correlations between 0.5-0.8 or 0.8 to 1 (parameter minCorr) for this simulation study. For each genomic region, we added additional irrelevant CpGs by sampling CpGs randomly from the genome. The number of random CpGs added were either the same as ncpgs (parameter fold = 1), or two times of ncpgs (parameter fold = 2). Therefore, by design of the experiment, the status of each CpG, i.e. whether they belong to a comethylated cluster or not, is known.
These parameter values yielded 12 simulation scenarios: ncpgs (3, 5, or 8) x minCorr (0.5-0.8 or 0.8-1) x fold (1 or 2). For each scenario, this process was repeated 10 times to generate a total of 120 simulation datasets.
Step 1 in the coMethDMR pipeline was used to identify co-methylated regions for each simulated genomic region. Supplementary Table 1 and Table 1 ). Figure   4 and 5 also showed that at rDrop = 0.4, both sensitivity and specificity were over 0.9 for all but one simulation scenario. Therefore, we set rDrop at 0.4 for subsequent analysis.
coMethDMR controls Type I error when testing association between methylation levels in the genomic regions with phenotype.
We conducted two simulation studies to assess the Type I error (i.e. false positive rate) of the proposed method. In Simulation study 2, we assume the genomic regions are pre-determined and we compared results using different statistical models for testing association of methylation levels with randomly generated phenotypes. In Simulation study 3, we assume the genomic regions are not pre-determined, and we determined Type I error for the entire coMethDMR pipeline. That is, we first identified comethylated regions, then tested these selected regions for association with randomly generated phenotypes.
Simulation study 2: We evaluated the Type I error rate of several currently available statistical methods, along with the newly-proposed random coefficient mixed model, by generating random phenotype data and test their association with genomic regions in a real DNA methylation dataset. More specifically, we compared the five statistical models listed in Table 1 : (1) To emulate correlation structure between different CpGs in real data, we generated simulation datasets using a real methylation dataset (GSE59685) as input. Lunnon et al. (2014) conducted an AD study that measured DNA methylation levels in four brain regions postmortem from 122 individuals using the Infinium HumanMethylation450K BeadChip platform (7) . For this Type I error analysis, we used prefrontal cortex methylation data from 27 control subjects. For each simulation dataset, we randomly generated an age value for each sample. In the following sections, we use the term pseudo age to refer to the computer-simulated age variable.
First, we select 10 CpG island genomic regions randomly. For each region, we generated pseudo age randomly from a Poisson distribution with mean 65, independently of the methylation data.
Therefore, by design of experiment, these pseudo age values are not associated with any methylation regions. This procedure was repeated 1000 times, to generate 10,000 simulation datasets (10 genomic regions x 1000 repetitions). Under the null hypothesis of no association between methylation and pseudo age, we expected the p-value distributions for a model to follow the uniform distribution, where 5% of the p-values would be less than 0.05, corresponding to a Type I error rate of 0.05.
In Figure 6 , the estimated Type I error rates were 0.1011 (GEE model), 0.0545 (linear model with mean summary), 0.0532 (linear model with median summary), 0.0404 (random coefficient mixed model) and 0.0002 (simple linear mixed model). We can see that the GEE model showed inflated false positive rate, with highest Type I error at around 0.1 . The inflated type I error rate by GEE model was also observed recently in simulation studies conducted by another group (19) . On the other hand, the simple linear mixed model in (4) was overly conservative, with Type I error around 0.0002. Among the models, the proposed random coefficient mixed model in (5) and the linear models with mean or median summary had type I error closest to 0.05.
Simulation study 3: We next determined Type I error rate for coMethDMR when genomic regions are not pre-determined. That is, we determined if the coMethDMR pipeline, which includes both identifying co-methylated methylation clusters, and testing methylation regions against phenotype using linear mixed models, would still have controlled Type I error rates. To this end, we first identified 4444 co-methylated genomic regions mapped to CpG islands. Next we selected 10 co-methylated regions randomly, and then repeated Simulation study 2 on these co-methylated regions. That is, for each comethylated region, pseudo age values were generated randomly from Poisson distribution with mean of 65 for each of the samples. This procedure was repeated 1000 times to generate 10,000 simulation datasets (10 co-methylated regions x 1000 repetitions). Suppl. Figure 1 shows that after selecting comethylated CpGs, Type I error remained well-controlled for both mixed models.
coMethDMR improves power substantially compared to fitting mixed model directly to methylation data
Simulation study 4: Because genomic region are typically defined a priori based on annotations, without regard to the methylation data sets to be analyzed, we expect only a subset of CpGs in a pre-defined genomic region would be associated with the phenotype. We hypothesized that power can be improved by selecting consecutive CpGs in the co-methylated region first. To assess the power of the models that had controlled Type I error rate (i.e. simple linear mixed model and random coefficient mixed model),
we performed a simulation study similar to Simulation study 2 described above, except by testing methylation levels in the genomic regions against randomly generated pseudo age that are ranked in the same order as the mean of methylation values in the co-methylated sub-region. Therefore, by design of the experiment, the values of pseudo ages of the samples are associated with co-methylated CpGs in each genomic region.
The results in Figure 7 show that for both mixed models, power improved substantially after selecting the co-methylated regions. Without selecting co-methylated CpGs, the random coefficient mixed model has more power. After selecting co-methylated CpGs, both models performed similarly, especially when the number of co-methylated CpGs was at least moderate (i.e. nCpGs >= 5) .
Random coefficient mixed model improves specificity when identifying differentially methylated regions
As mentioned above, a key challenge in unsupervised approaches for identifying DMRs is their lack of specificity. In particular, it is desirable to identify significant genomic regions that include only CpG probes significantly associated with the continuous phenotype and exclude those CpGs not related to phenotype. To further evaluate the specificity of different statistical models on real methylation data, we next applied the five models described above as well as several supervised approaches (bumphunter (17) To understand how the random coefficient mixed model improves specificity, note that this model specifically models co-variation of the slopes. In Figure 3 and subsection "Random coefficient mixed model", the CpG specific slopes are modeled by random effects , where we assume ~ 0, .
The variations in the CpG specific slopes will be captured by estimated variance component for the random effects , which contributes to variance of , the slope main effect for the continuous phenotype (e.g. disease stage). Thus, genomic regions with more consistent differential changes in methylation levels among the CpGs will have a lower value for , corresponding to a lower value for variance of , and yielding a more significant p-value for the slope main effect. On the other hand, regions with outlier CpGs would have large variances for , resulting non-significant p-values for the slope main effect.
To further illustrate the effect of modeling heterogeneity in CpG slopes, consider the 5 CpGs located within the CGI at chr13:115046754-115048034 ( Figure 9 ). To simplify this example, we tested methylation M values in this region against disease stage, without controlling for any covariate variables.
The results showed that the p-values for this region are 2 . 42 10 (IMA_mean), 0.0154 (IMA_median), 1. 87 10 (GEE in Aclust), and 0.0046 (simple linear mixed model in seqlm and coMethDMR_simple). However, note that the significance of this region is driven by only 1 CpG, cg12513911 (light blue). On the other hand, the p-value for random coefficient model in coMethDMR_randCoef is 0.315, which indicates that the random coefficient mixed model correctly classified this CGI as a non-significant region.
This example shows that without specifically modeling variances in the slopes, the significant regions identified might have large heterogeneity in individual CpG slopes. As a result, the region may include a substantial number of non-significant CpGs. In particular, region-wise p-values using conventional unsupervised methods can be driven by a single outlier CpG that has strong association signal, which does not constitute a DMR by definition. In contrast, the proposed random coefficient mixed model would prioritize genomic regions where the mean methylation trajectory for multiple CpGs is highly correlated with continuous phenotype, and the heterogeneity in trajectories for individual CpGs within the region is low.
coMethDMR identifies biologically-meaningful DMRs
To evaluate the biological plausibility of DMRs identified by different methods, we next examined the analysis results for testing methylation levels with AD stages in the Lunnon et al. dataset. After adjusting for age, sex, batch, and estimated proportions of neurons, coMethDMR_simple and coMethDMR_randCoef identified 10 and 4 significant regions at 5% false discovery rate (FDR), respectively. We compared these results with significant DMRs identified by other methods, including the IMA_mean, IMA_median, Aclust_GEE and seqlm methods. We also tested several supervised methods, including DMRcate, bumphunter, probelasso, and comb-p. Figures 10-11 show the overlap of significant regions identified by these methods and the coMethDMR_simple and coMethDMR_randCoef methods, respectively. The seqlm method (unsupervised) and DMRcate, bumphunter, and probeLasso methods (supervised) were excluded from these figures because they did not identify any DMRs at 5% FDR.
The results showed that among all other methods, results from IMA_median had the most overlap with both coMethDMR_simple and coMethDMR_randCoef results. In particular, half of the significant DMRs identified by coMethDMR_simple (5 out of 11) and coMethDMR_randCoef (2 out of 4) were also selected by IMA_median (Figure 10-11 ) This is most likely due to the fact that IMA_median is less affected by trajectories of outlying CpGs within a genomic region than other methods. Results from Aclust_GEE also had substantial overlap with coMethDMR results. However, this could be due to the fact that Aclust_GEE method identified a large number of DMRs. Given that the Type I error rates for Aclust_GEE was inflated ( Figure 6 ), many of the significant DMRs could be false positives. Compared to the overlap between comb-p and coMethDMR_randCoef, results from coMethDMR_simple agreed more with the supervised method comb-p ( Figure 12 ), probably because neither method accounts for heterogeneities in CpG slopes. Table 2 shows the significant regions identified by coMethDMR_simple and coMethDMR_randCoef. For the DMRs identified by coMethDMR_randCoef, the most significant region is in the gene body of SEPT5, a brain-expressed cytoskeletal organizing gene that was nominally associated with AD (29) in family-based GWAS studies and has been shown by proteomic analysis to have altered levels in brains of AD patients (30) . The second region is in KIF1A, a member of the kinesin family that transports cargo along axonal microtubules. One of KIF1A's major roles is to transport BACE1 in neuronal axons (31) . The third gene, PCNT, has also been linked to altered methylation in AD brains (6) . The fourth region is in the 3' UTR of the HOXA3 gene, which is part of a gene cluster on chromosome 7. Recently, aberrant methylation of this region has been shown to be associated with AD neuropathology in multiple AD EWAS datasets (32) .
The coMethDMR_simple model identified several more genes that were previously implicated in AD etiology. For example, the MBP gene encodes myelin sheath of oligodendrocytes and Schwann cells in the nervous system. Brains from patients with AD had significant loss of intact MBP. Myelin disruption is an important feature of Alzheimer's disease (AD) that contributes to impairment of neuronal circuitry and cognition (33, 34) . The RHBDF2 gene was previously found to be associated with AD stages in a different large scale methylation study (6) . Another important gene, ATP2A3, encodes one of the SERCA Ca(2+)-ATPases, which are involved in maintenance of low intraneural Ca2+ concentration. The multifunction of this pump was recently found in brains of AD subjects (35) . Finally, the HOXB9 and SPN genes appears to be involved in immunological and inflammatory process that may relate to AD pathophysiology (36) . Taken together, these results suggest that use of coMethDMR can identify disease-relevant genes and replicate previous single-site and regional methylation analyses (in the case of the PCNT, RHBDF2 and HOXA3 genes).
DISCUSSION
Although a number of methods have been proposed, identifying differentially methylated regions remains a challenging task because of the complexities in DNA methylation data. One such challenge with supervised DMR-identification methods is their lack of power when the difference in beta values between two groups was small but consistent (i.e. difference in mean beta values is less than 0.05) (25) . This is likely because supervised methods scan the genome to identify regions with adjacent low p-values, so a number of positions that pass a multiple-comparison-corrected significance threshold are required. On the other hand, unsupervised methods, which define genomic regions first and then test them against phenotype, tend to lack specificity and often prioritize irrelevant genomic regions.
In this paper, we have presented coMethDMR, an unsupervised method for identifying differentially Table 2 . Differentially methylated regions associated with AD stages identified by coMethDMR.
Supplementary Table 1 . Simulation study to identify optimal rdrop parameter in first step of coMethDMR pipeline. For each simulation scenario, rdrop parameter with red font corresponds to best performance. Figure 6 . Type I error rates in the absence of differential methylation for different statistical models.
Shown above the bars are proportions of CpG island genomic regions with p-values less than 0.05, for association with randomly generated "age" from Poisson distribution with mean 65, average over 10,000 simulation datasets. Under the null hypothesis of no association, we expected p-values to follow a uniform distribution, so methods that control type I error at nominal level would be close to the red line. 
